spacer
home > ict > winter 2017 > reality check
PUBLICATIONS
International Clinical Trials

Reality Check

Randomised controlled trials (RCTs) are the gold standard for drug approval to establish the efficacy of interventions, and pragmatic RCTs measure their effectiveness. Real world studies are referring to pragmatic RCTs for the purpose of this article.

In recent years, the UK has seen a shift in the NHS treatment of patients with ongoing chronic medical conditions from secondary to primary care. The NHS Constitution has promised that all eligible prospective participants are offered the choice and opportunity to take part in relevant studies (1). Therefore, in order to cultivate these developments and truly represent the study population, there needs to be a move away from traditional research studies that extrapolate results in other settings, to real world evidence obtained from patients in both secondary and primary care. This is because it could be argued that patients who attend research facilities are in an ‘artificial’ controlled environment, rather than reflecting real life clinical practice. Often, with traditional RCTs, many subjects have a single disorder under examination – meaning those with several co-morbidities are excluded and results can only be true in those with solitary disease profiles.

Real World Studies

This is where real world studies can prove invaluable. They are able to combat the above issues, plus complement the established phases of trial methodology by widening the inclusion criteria to include subjects with several comorbidities – thus allowing closer examination of real life subjects as opposed to generalisation of a population. Conversely, the data available in primary care are comprehensive, and strict selection of data values is necessary to avoid any unethical collection of data that would be discounted at the analysis stage.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julie Millar is CK Aspire’s Community Research Nurse Team Lead. Prior to this role, she worked in the NHS in Renal Medicine and as a Community Practice Nurse specialising in respiratory. Julie holds a Bachelor’s in Specialist Practitioner/ Practice Nursing.

Gaynor Mates is currently employed as a Clinical Research Nurse for CK Aspire, working on a real world study. Before joining the company, she worked with the NHS for 30 years, the last 17 of which she spent as a Lead Respiratory Nurse Specialist. Gaynor holds an MSc and a BSc in Respiratory Disease Management and is an Independent Nurse Prescriber.

Louise Doyle
is Senior Research Safety Officer at CK Aspire. Having qualified as a Midwife in 2008, she has worked as a researcher in maternity, infection control, paediatric oncology and respiratory studies. Louise holds a Postgraduate Diploma in Clinical Research.

spacer
Julie Millar
spacer
spacer
spacer
Gaynor Mates
spacer
spacer
spacer
Louise Doyle
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Acquires KWS BioTest

WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

12th Annual Paediatric Clinical Trials

19-20 March 2018, Copthorne Tara Hotel, London, UK

SMi is pleased to present the return of their 12th annual Paediatric Clinical Trials Conference taking place on 19th – 20th March 2018, London, UK.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement